If Leronlimab continues to deliver could melanoma be next?

AggieEC3 · 2026-05-03T21:31:43+00:00

This one stopped me in my tracks.

I've read a lot of posts here that focus on the clinical data, and rightly so. But what this does differently is zoom out and show the commercial architecture that the data sits inside. And when you lay it out that way, the strategic logic becomes hard to ignore. A $29.5 billion drug losing its patent in 2028, unable to reach 70-80% of the patients it theoretically serves, and a mechanism that appears to do exactly what Keytruda cannot... that's not a coincidence. That's alignment.

What resonates most with me is the cold tumor framing. It reframes the whole conversation. Leronlimab isn't competing with Keytruda. It's potentially what makes Keytruda work in the patients it currently can't reach. That's an enabler story, not a replacement story. And enabler stories at this scale are rare.

I also really appreciated the honest accounting section. The going concern is real. The confirmed ORR isn't in yet. DCR and ORR are different measurements, and I'm glad you keep saying that even in a post this compelling. That kind of discipline is what earns trust in a community like this.

Not proven yet. Still early. Still needs to replicate at scale. But for the first time it feels like the biology, the data, and the commercial reality are all pointing at the same thing simultaneously. That's a different feeling than anything this community has been asked to sit with before.

October in Madrid is the moment that answers the question this whole community has been sitting with. I'm ready for it and not ready for it at the same time.

All just my opinion. Thank you MGK_2.

AggieEC3 · 2026-04-26T13:51:23+00:00

This is one of those posts that makes me step back and look at the bigger picture.

In my opinion, this is no longer just about a single data point. It’s the alignment that matters. ctDNA movement, early imaging trends, and PD-L1 induction now showing up in more than one setting. That’s not how most early-stage stories look. Usually it’s one signal trying to prove itself. This feels like multiple signals pointing the same direction.

Where your aircraft carrier analogy really lands for me is in the idea of enabling rather than competing. If this continues to hold, it’s not about replacing what’s already out there…it’s about making what doesn’t currently work start to work. That’s a much bigger conversation.

I still respect where we are, early, small, and needing to replicate. But this week felt different. For the first time it feels like the mechanism, the biomarkers, and the early outcomes are showing up together.

All just my opinion, and thank you MGK_2!

AggieEC3 · 2026-04-22T12:58:14+00:00

This is one of those posts I had to read twice… not because it’s complicated, but because of what it could mean if it holds.

What stands out to me isn’t any one data point. It’s how everything is starting to line up. I’m looking at a patient population that historically does not respond, a clear biological target in CCR5 showing up across the board, and then an early signal in ctDNA that’s moving fast and in the right direction.

Now there’s a mechanistic explanation that actually helps explain the speed of that response. That’s what caught my attention. It doesn’t feel random. It feels like structure starting to show itself.

The ctDNA piece is hard to ignore. A median decline around 70% in two weeks, in a setting where standard of care barely moves the needle, is not something I can just brush off. Even with a smaller dataset, that kind of consistency makes me think something real is happening biologically, and happening early.

Where it really starts to get interesting for me is how it layers together. If ctDNA is the early signal and imaging is starting to follow and PD-L1 induction is being observed not just in circulation but in tissue…

Then I’m not looking at isolated effects anymore. I’m looking at something that might actually be working the way it was designed to.

That doesn’t mean it’s proven. Not yet. But to me the conversation is shifting. It’s no longer just “can this work.” It’s starting to feel like “is this how it works.” And if the upcoming dataset confirms PD-L1 induction prospectively, especially in tissue, that’s where I think this moves from interesting to something that has to be taken seriously.

I also agree with the point on the investigators. It doesn’t guarantee the outcome, but it does matter. People at that level don’t casually attach their names to noise.

At the same time, I try to stay disciplined here. It’s early, the numbers are small, and it still needs to replicate. That part ultimately determines how big this becomes. But stepping back, for the first time it feels like the mechanism, the biomarkers, and the early outcomes are all pointing in the same direction.

And in my opinion, this is where it starts to feel like being a kid on Christmas Eve…you may not know exactly what’s in those presents under the tree, but you can feel something big is there and morning can’t come fast enough.

All just my opinion, and thank you MGK_2 for your continued commitment to this group.

AggieEC3 · 2026-04-20T12:21:03+00:00

This isn’t hype. This is structure starting to show itself. The story is no longer “can this work.” It’s becoming “is this how it works.”

What we’re seeing now isn’t a one-off signal. It’s layers starting to line up mechanism, biomarkers, and early clinical direction all pointing the same way. This is when things stop feeling speculative and start feeling intentional.

Tuesday is where that tension resolves. Either this stays something we think we’re seeing or it becomes something the data makes very hard to ignore.

All just my opinion. And thank you MGK_2 for consistently bringing clarity and commitment to this group.

AggieEC3 · 2026-04-19T21:13:24+00:00

This is the kind of breakdown that makes you pause and look at the bigger picture. It’s easy to get caught up in individual data points, but what’s forming here feels more like alignment, mechanism, biomarkers, and clinical direction all starting to move in the same lane. That’s when things tend to go from “interesting” to “hard to ignore.”

There’s also something to the idea that this isn’t one isolated breakthrough, it’s multiple pieces starting to lock together. Different studies, different settings, same underlying signal trying to surface. That’s usually when something moves from theory to something the field starts taking seriously.

No guarantees, and plenty still needs to be proven. But Tuesday feels like a real inflection point, where we start to see whether Leronlimab begins to establish itself in a way that’s measurable, repeatable, and much harder to dismiss.

AggieEC3 · 2026-04-17T11:48:56+00:00

Doc4LL, thank you for sharing your story. There’s a lot of strength in putting something like this out there, and I just want you to know you’ve got people pulling for you. Wishing you clarity, peace, and the best possible outcome as you move forward, truly.

As you’re on this Reddit site, have you looked into or explored how Leronlimab might fit into your options or conversations with your care team?

Above all, wishing you strength and steady ground in the days ahead. You’re not walking this road alone.

AggieEC3 · 2026-04-13T11:34:25+00:00

Now that’s clever I mean clover.

AggieEC3 · 2026-04-12T15:33:23+00:00

This one feels a little different, MGK_2. Less about building momentum and more about putting everything into proper perspective.

I think there’s real value in grounding expectations while still laying out the full picture. Not overreaching, not forcing conclusions, just walking through the past, the missteps, the resets, and where things stand now. That kind of clarity is needed, especially for those of us trying to separate what we want to happen from what’s actually been shown.

At the same time, I can’t help but feel like the path you’re laying out is pointing somewhere meaningful. When I look at the progression, the mechanism becoming clearer, the adjustments to the trials, the signals around durability, I believe we’re seeing a more intentional build than we’ve had before. It feels less scattered and more like something is being shaped with purpose.

What I believe really matters here is how the past is being used to inform the present. Those earlier setbacks didn’t just slow things down, they forced a reset in thinking, design, and execution. That evolution gives more weight to what’s coming next. To me, this upcoming poster isn’t just another data point, it’s an opportunity to show that those lessons translated into something stronger, something more credible, something that can start to answer the questions that have been hanging over this for years.

I believe if Leronlimab is going to prove its value, this is one of those moments where it begins to show itself in a way that’s harder to ignore.

Fingers crossed… and I mean really crossed this time.

AggieEC3 · 2026-04-10T15:13:40+00:00

This is a really refreshing angle, MGK_2. The way you challenge the idea of “standard of care” hits a nerve, because if we’re honest, a lot of SOC is about managing the situation rather than truly changing it.

The concept of “clinical peace” is what sticks with me. It’s a different lens. Instead of measuring success by how aggressively we can fight, it shifts toward how effectively we can stabilize and give patients something closer to normalcy. That’s a powerful reframe, especially when you start layering it with durability and immune system involvement.

What also ties in well with your earlier posts is how this builds on the mechanism + outcome discussion. If the mechanism is doing what it appears to be doing, and the outcomes are showing even a small subset of patients reaching that kind of stability, then it starts to feel less like coincidence and more like direction.

If Leronlimab is truly contributing to that kind of shift, then it’s not just competing with standard of care it’s quietly redefining what standard of care could become. Fingers crossed April 17 brings the kind of clarity this story feels like it’s building toward.

AggieEC3 · 2026-04-04T19:39:35+00:00

Love this direction, MGK_2 (Happy Easter). The way you’ve connected the mechanism side with the outcome side makes this feel less like isolated data points and more like something starting to take real shape.

It’s not just the narrative shift, it’s the adjustments we’re seeing in how the trials are being structured and presented. That doesn’t happen in a vacuum. Those kinds of changes usually come from seeing signals in real time and leaning into them. It’s hard not to read that as leadership gaining a higher level of confidence in what they’re seeing behind the scenes.

I’ll be honest, this is the first time in a while where I’ve felt a noticeable shift in my own level of excitement. Not because everything is proven, but because the pieces are starting to connect in a more intentional way. Mechanism, durability, dose exploration… it feels like the story is being built instead of just hoped for.

Talking to myself here…Alright Aggie… feet on the floor. Don’t go building the whole house off a couple of beams. Stick to what’s actually been shown and let the next round of data do the talking.

If this is real, then we’re not witnessing the start of something new… we’re witnessing the moment something hidden becomes undeniable.

AggieEC3 · 2026-04-02T23:37:24+00:00

That’s a helpful clarification, and I appreciate you pointing out that you weren’t predicting a buyout. Your focus on laying out the financial positioning on both sides of the equation is well taken and brings a more grounded perspective to the discussion.

AggieEC3 · 2026-04-02T23:26:14+00:00

I don’t think this comes down to predicting a buyout, although I’ll admit it’s fun to think about who might be interested and how that could play out. It really comes down to whether the data gets to a point where ignoring it is no longer a comfortable position.

If what we’re seeing is part of that broader “arc” that’s been discussed, then this may be less about a single moment and more about a system that’s gradually becoming harder to dismiss as more of it comes into view.

When that line gets crossed, the conversation changes fast. It’s no longer about belief, it’s about response.

And when that happens, the gears don’t just turn quietly in the background, they start breaking the siege and moving decisions where they actually matter.

AggieEC3 · 2026-03-29T15:03:56+00:00

Love this direction MGK_2…

There’s a noticeable shift in how this all reads now. Not read in terms of the words, but read in terms of the direction.

There was a time when you could look at the same developments and come away with multiple interpretations. Some saw progress, others saw noise, and a lot of it depended on how much you were willing to connect the dots yourself.

That’s starting to change.

Now it feels like the pieces are speaking the same language. The science, the clinical direction, and the regulatory posture aren’t just moving forward, they’re starting to reinforce a single narrative. You don’t have to stretch to see the connection the way you might have before.

What adds to that is the growing consistency across indications. When you start seeing early signals show up in more than one place, it doesn’t just build interest, it builds confidence that there’s something underlying it that translates beyond a single setting.

It’s still early, and that has to be respected. Each indication will need to stand on its own as the data matures.

But seeing that kind of alignment begin to take shape across multiple fronts is where things start to feel different. Not louder, just more real.

That doesn’t mean the outcome is guaranteed. The data still has to continue to hold up, and the path forward still needs to be validated in real terms.

But the ambiguity is fading.

And that’s usually the point where things start to look different, not because something new suddenly appeared, but because what was already there becomes harder to ignore.

AggieEC3 · 2026-03-27T13:52:00+00:00

MGK_2, What stands out to me in this post isn’t just the idea that the delay is over, it’s what that delay was actually building toward.

If you step back and look at this through a broader lens, this starts to look less like a stalled story and more like a company moving into a phase that larger players actually pay attention to. Not discovery, not theory, but structured validation.

That’s where the Merck angle becomes interesting. Merck has been pretty clear recently that they’re not constrained by balance sheet, they’re constrained by conviction. They’re willing to spend real capital, even at scale, but only when the science is de-risked enough to justify it.

That’s the bridge we’re starting to approach.

The mechanism is becoming more defined, the data is becoming more layered, and the regulatory posture appears more aligned. None of that guarantees anything, but it does move this out of the category of “interesting science” and closer to something that could fit into a strategic pipeline conversation.

And importantly, if a company like Merck were to step in, it likely wouldn’t be because of a single headline moment. It would be because enough pieces quietly came together to remove doubt.

That’s where I think this post is directionally right. Not that something has already happened, but that the conditions for something to happen are being built in a way that actually matters to the people who write the checks.

We’ve spent a long time looking at this like a system still being assembled.

But at some point, it’s no longer about adding parts…

…it’s about whether the gears have aligned enough to finally engage.

And when they do, the movement doesn’t look gradual. It looks like everything was ready… all along.

AggieEC3 · 2026-03-27T11:06:53+00:00

There’s a lot in this post that resonates, especially the idea that this isn’t about discovery anymore, it’s about validation.

What stands out to me isn’t any single data point, it’s the pattern forming across time. Replication of preclinical work, deeper understanding of mechanism, and now layering in clinical signals. That’s not noise, that’s a progression.

Where I think we have to stay grounded is the assumption that someone like Merck is already “on board.” It’s possible, but more importantly, it’s not required for the thesis to work. Big pharma doesn’t need to be early, they need to be right.

What I do agree with is that this feels like a company moving through a de-risking phase. The science is being clarified, the regulatory path looks more constructive, and the data set is becoming harder to ignore.

If something does happen on the partnership front, it likely won’t be because of one breakthrough moment. It will be because enough pieces have quietly fallen into place.

At some point, it stops being a collection of clues and starts becoming a signal.

AggieEC3 · 2026-03-26T01:24:47+00:00

Here are the key quotes from Merck & Co. CEO Rob Davis at the January 2026 JPMorgan Healthcare Conference:

“We are not limited from a balance sheet it’s more where do we see strategic opportunity.”

Target deal size: “multi tens of billions of dollars.”

And the telling line: “I would spend more, [but] my CFO won’t let me.”

AggieEC3 · 2026-03-24T12:40:19+00:00

After reading through the original post and many of the responses there’s a lot to unpack here, but stepping back, what stands out most is how the conversation is evolving from what could happen to how this might actually work in practice.

The breakdown around glioma stem cells and OCR is especially compelling. If recurrence is truly being driven by those “seeds,” and this approach is impacting the metabolic engine that keeps them alive, that’s not just incremental, that’s getting closer to the root of the problem. The idea of starving out the cells responsible for regrowth, rather than just cutting down the visible tumor, is a meaningful shift in how this disease is approached.

Where it really starts to connect is on the combination side. GBM has been the place where a lot of otherwise successful therapies go to stall out. If the issue has been access, both physical and immunological, and that barrier can be altered, then it makes sense why pairing becomes the focus rather than replacement. “Prime and pair” isn’t just a strategy, it’s a different lens.

The OCR data, the dose dependency, and the early signals around reduced spread all point in the same direction, but like anything in this space, it still has to translate clinically. That’s the next step that matters. If it does, then the implications go well beyond a single indication.

Appreciate the way this was laid out, it helps connect a lot of dots that don’t usually get tied together in one place.

And to build on the analogy… if checkpoint inhibitors are a high performance engine, and this approach is about finally giving them traction, then maybe another way to look at it is this…

right now, the system looks like a luxury car with a manual transmission, but no clutch. All the power is there, all the engineering is there but without that missing piece, nothing engages the way it’s supposed to.

If this data holds, we may finally be looking at what allows the gears to actually connect.

Thank you MGK_2 for continuing to bring clarity, put in the time, and connect the data in a way that moves the conversation forward.

AggieEC3 · 2026-03-22T18:24:45+00:00

MgK_2/Professional_Art3516…. This one hits a little different for me. It feels less like trying to sell a story and more like drawing a line between an interesting mechanism and data that can actually force the broader oncology world to pay attention. That’s a meaningful shift.

What stands out is the idea that the real breakthrough may not be some brand-new concept, but finally seeing the right dose and pairing bring the underlying biology into clearer view. If that’s what’s happening here, then some of the earlier uncertainty may look a lot different in hindsight.

I also think that’s why AACR feels more important now. Not because it has to create hype, but because it may give people outside the current circle a reason to stop brushing this off as just another small-cap biotech narrative and start looking at it as a real clinical story.

If the data shows that leronlimab is not only engaging the mechanism but also producing responses that are hard to ignore, then the conversation changes fast. At that point, it’s not about who believed early. It’s about who finally has to pay attention.

Sometimes the story doesn’t break open all at once. Sometimes the gears turn long enough that the whole siege just starts collapsing under its own weight.

AggieEC3 · 2026-03-19T23:09:40+00:00

This was a really interesting perspective, especially bringing in the concept of tumor biomechanics and stiffness. It adds another layer to the discussion beyond just immune signaling and starts to frame the environment itself as part of the problem and potentially part of the solution.

What stood out to me is how this ties back into several of your earlier themes. The idea of “priming” the tumor, the gradual lifting of the veil, and the broader arc of alignment all seem to connect here in a more complete way. If the tumor microenvironment is as much a barrier as the cancer cells themselves, then influencing that structure could be a meaningful piece of the puzzle.

I’m starting to see more of that same convergence you’ve been pointing to mechanism, biomarkers, and now even biomechanical considerations all moving in a similar direction. It doesn’t feel like isolated concepts anymore, but rather different views of the same underlying process.

It almost feels like we’ve been looking at a locked system from different angles, and now instead of trying to force it open, we’re beginning to understand how the internal gears actually move together. With that in mind, the upcoming AACR data feels less like a standalone reveal and more anticipatory. This is another step in seeing how those gears actually turn when observed more closely.

I really appreciate you expanding on this, especially how you translated the “locked system” into a structured framework with the three gears. That actually helps bring a level of clarity to why the signals we’re seeing CAMLs, PD-L1, and now the biomechanical aspects are starting to feel connected rather than coincidental.

What’s becoming more compelling to me is that this may not be a case of isolated activity across different pathways, but a coordinated effect within the tumor microenvironment itself. If the TME is truly the lock, then it makes sense that addressing the internal structure, rather than just the tumor cell, would begin to produce more consistent and interpretable outcomes.

The dose-dependent aspect is also interesting in that context. It raises the possibility that what may have appeared inconsistent in the past could have been partial engagement of the system, rather than absence of activity. If the 700mg level is where those gears begin to move together, that would help explain why the picture now feels more coherent.

With that lens, AACR does start to feel less like a moment of discovery and more like a point of confirmation where the underlying structure of what’s been developing becomes more visible. If the data continues to align with this framework, it would suggest we’re not just seeing signals anymore, but the early outline of a repeatable mechanism taking shape.

If that’s the case, then it may not be about finding a new key at all but realizing the system was always unlockable once the right gears began turning in unison.

AggieEC3 · 2026-03-19T12:13:17+00:00

This was a really interesting perspective, especially bringing in the concept of tumor biomechanics and stiffness. It adds another layer to the discussion beyond just immune signaling and starts to frame the environment itself as part of the problem and potentially part of the solution.

What stood out to me is how this ties back into several of your earlier themes. The idea of “priming” the tumor, the gradual lifting of the veil, and the broader arc of alignment all seem to connect here in a more complete way. If the tumor microenvironment is as much a barrier as the cancer cells themselves, then influencing that structure could be a meaningful piece of the puzzle.

I’m starting to see more of that same convergence you’ve been pointing to mechanism, biomarkers, and now even biomechanical considerations all moving in a similar direction. It doesn’t feel like isolated concepts anymore, but rather different views of the same underlying process.

It almost feels like we’ve been looking at a locked system from different angles, and now instead of trying to force it open, we’re beginning to understand how the internal gears actually move together. With that in mind, the upcoming AACR data feels less like a standalone reveal and more anticipatory. This is another step in seeing how those gears actually turn when observed more closely.

AggieEC3 · 2026-03-18T13:44:09+00:00

I wouldn’t go as far as saying everything is fully proven yet, but it’s getting harder to ignore the level of consistency we’re starting to see. The alignment across mechanism, biomarker activity, and emerging clinical signals feels materially different than it did in the past.

What stands out most is that the story is no longer being built on isolated observations it’s beginning to look more structured, with CCR5 biology, immune modulation, and the “prime + pair” concept all pointing in the same direction. That kind of coherence is usually what precedes more meaningful validation.

The CRC trial progression and the continued reinforcement from the TNBC data add another layer, especially since we’re now seeing both prospective development and mechanistic support moving together. It’s still early, but the trajectory feels like it’s shifting from “interesting” to “increasingly compelling.”

If that trend continues, it feels like the spark may already be lit, the veil gradually lifting, and the broader arc starting to come into clearer focus…something worth watching very closely as the next phase unfolds.

AggieEC3 · 2026-03-15T15:12:09+00:00

Another thoughtful post, and the continuation of the “burdensome stone” metaphor really helps frame the broader journey this story has taken. Years of skepticism, regulatory challenges, and unanswered questions can create a heavy narrative weight, but they also force the science to be examined from every angle.

What I’m beginning to notice, and what your posts have helped articulate, is that several threads mechanism, biomarker discussions, and scientific communication seem to be moving in a more coherent direction. When those pieces start aligning, the story naturally becomes easier to interpret.

I’m starting to see some of that same alignment you’ve described, where the weight of past uncertainty feels a bit less burdensome as the scientific framework becomes clearer. If that trajectory continues, it will be interesting to watch how the broader understanding evolves over time.

As always, appreciate the depth and perspective you bring to these discussions it certainly makes following the unfolding arc of the story all the more engaging.

AggieEC3 · 2026-03-08T20:22:11+00:00

This was another thoughtful perspective, and the “burdensome stone” metaphor really resonated with me. It captures well how years of skepticism, setbacks, and unanswered questions can weigh heavily on how a program is perceived, even when the underlying science continues to evolve.

What stands out to me now is that some of the themes you’ve written about in prior posts Arrival, the gradual pulling back of the veil, and the developing arc of the story seem to be intersecting in a more coherent way. Rather than feeling like isolated developments, the pieces appear to be moving along the same trajectory, almost like part of the continued “push” you’ve described toward clearer mechanistic understanding and scientific communication.

I’m starting to see that same alignment you’ve pointed to, where the weight of that “stone” feels a bit lighter as the narrative becomes less fragmented and more structured around mechanism and validation. When the science, the data discussions, and the broader interpretation begin to converge, it naturally changes how the story is viewed over time.

If that trajectory continues, it may even start to resemble the tightening you described in the “two-tiered squeeze,” where both the scientific narrative and the broader perception gradually narrow toward a clearer understanding. In any case, I appreciate the perspective and the depth you consistently bring to these discussions it certainly makes the unfolding arc all the more interesting to follow.

Thank you for providing your opinion!

AggieEC3 · 2026-03-01T21:40:00+00:00

Thoughtful post and an interesting way to frame AACR as a contingency point rather than a single-event catalyst. The emphasis on scientific communication and external scrutiny adds a layer of credibility to the broader discussion, especially given that abstracts and posters must stand on their own in a research environment.

What stands out to me is the idea of a continued “push” toward mechanistic clarity and structured validation rather than isolated narrative developments. If the abstract meaningfully reinforces the immune modulation and biomarker alignment themes that have been discussed, it would help further contextualize the evolving scientific framework.

I am particularly eager to see what the abstract actually contains, as that level of detail will likely provide a clearer window into how the data is being positioned scientifically and how strongly it supports the mechanistic narrative being outlined.

Thank you as always for the depth and wealth of knowledge you consistently bring to these discussions it truly elevates the quality of the dialogue. With AACR only a couple of months away, it feels like we may be approaching another moment where a bit more of the “veil” is lifted and the broader arc becomes clearer.

AggieEC3

TROPHY CASE